Anti-CXCL9 antibody [EPR26512-118]
- BOND RX™ Validated
- 20ul selling size
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(5 Publications)
Anti-CXCL9 antibody [EPR26512-118] (ab290643) is a rabbit monoclonal antibody detecting CXCL9 in Western Blot, Flow Cytometry (Intra), Flow Cytometry, IP, IHC-P, ICC/IF. Suitable for Human.
- Biophysical QC for unrivalled batch-batch consistency
View Alternative Names
CMK, MIG, SCYB9, CXCL9, C-X-C motif chemokine 9, Gamma-interferon-induced monokine, Monokine induced by interferon-gamma, Small-inducible cytokine B9, HuMIG
- IHC-P
Supplier Data
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CXCL9 antibody [EPR26512-118] (AB290643)
Immunohistochemical analysis of paraffin-embedded Human cerebrum tissue labelling CXCL9 with ab290643 at 1/100 (5.38 ug/ml) followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection) was used. Negative control : no staining on human cerebrum. The section was incubated with ab290643 for 30 mins at room temperature.The immunostaining was performed on a Leica Biosystems BOND® RX instrument Counterstained with Hematoxylin.
Secondary antibody only control : Secondary antibody is a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection) was used.
Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins
- ICC/IF
Lab
Immunocytochemistry/ Immunofluorescence - Anti-CXCL9 antibody [EPR26512-118] (AB290643)
Immunofluorescent analysis of 4% paraformaldehyde-fixed, 0.1% Triton X-100 permeabilized KATO III (Human stomach spherical) cells labelling CXCL9 with primary antibody anti-CXCL9 (ab290643) at 1/50 dilution, followed by Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) preadsorbed (ab150081) secondary antibody at 1/1000 dilution. Confocal image showing increased cytoplasmic staining in KATO III cells treated with IFN gamma (human) (100 ng/ml) and TNF alpha (human) (100 ng/ml) for 16 hours. Anti-alpha Tubulin mouse monoclonal antibody - Microtubule Marker (Alexa Fluor® 594) (ab195889) was used to counterstain tubulin at 1/200 dilution. The nuclear counter stain is DAPI (blue).
- IHC-P
Supplier Data
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CXCL9 antibody [EPR26512-118] (AB290643)
Immunohistochemical analysis of paraffin-embedded Panel A THP-1 cell tissue labelling CXCL9 with ab290643 at 1/2000 (0.269 ug/ml) followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection) was used. Positive staining on (A) THP-1 cells treated with a combination of IFN-γ (200ng/ml, 24h) and LPS (50ng/ml, 24h); no staining on (B) untreated THP-1 cells. The section was incubated with ab290643 for 30 mins at room temperature.The immunostaining was performed on a Leica Biosystems BOND® RX instrument Counterstained with Hematoxylin.
Secondary antibody only control : Secondary antibody is a ready to use LeicaDS9800 (Bond® Polymer Refine Detection) was used.
Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins
- IHC-P
Supplier Data
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CXCL9 antibody [EPR26512-118] (AB290643)
Immunohistochemical analysis of paraffin-embedded Human prostate carcinoma tissue labelling CXCL9 with ab290643 at 1/100 (5.38 ug/ml) followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection) was used. Positive staining on human prostate carcinoma. The section was incubated with ab290643 for 30 mins at room temperature.The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with Hematoxylin.
Secondary antibody only control : Secondary antibody is a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection) was used.
Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins
- Flow Cyt (Intra)
Supplier Data
Flow Cytometry (Intracellular) - Anti-CXCL9 antibody [EPR26512-118] (AB290643)
Intracellular flow cytometric analysis of 4% paraformaldehyde, 90% methanol THP-1 (Human monocytic leukemia monocyte) treated with 200ng/ml IFN gamma and 50ng/ml LPS for 24h (Right) labelling CXCL9 with ab290743 at 1/50 dilution/ Untreated control (Left). Goat Anti-Rabbit IgG (Alexa Fluor® 488, ab150081) at 1/2000 dilution was used as a secondary antibody.
- IHC-P
Supplier Data
Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-CXCL9 antibody [EPR26512-118] (AB290643)
Immunohistochemical analysis of paraffin-embedded human lung carcinoma tissue labelling CXCL9 with ab290643 at 1/100 dilution followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection). Positive staining on human lung carcinoma. The section was incubated with ab290643 for 30 mins at room temperature.The immunostaining was performed on a Leica Biosystems BOND® RX instrument Counterstained with Hematoxylin.
Secondary antibody only control : Secondary antibody is a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection) was used.
Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins
- IP
Supplier Data
Immunoprecipitation - Anti-CXCL9 antibody [EPR26512-118] (AB290643)
CXCL9 was immunoprecipitated from 0.35 mg KATO III (human gastric carcinoma) treated with 100ng/ml IFN gamma and 100 ng/ml TNF alpha for 16 hours whole cell lysate 10 ug with ab290643 at 1/30 dilution. Western blot was performed on the immunoprecipitate using ab290643 at 1/1000 dilution. VeriBlot for IP secondary antibody(HRP)(ab131366) was used at 1/5000 dilution.
Lane 1 : KATO III (human gastric carcinoma) treated with 100ng/ml IFN gamma and 100 ng/ml TNF alpha for 16 hours whole cell lysate 10 ug
Lane 2 : ab290643 IP in KATO III treated with 100ng/ml IFN gamma and 100 ng/ml TNF alpha for 16 hours whole cell lysate
Lane 3 : Rabbit monoclonal IgG (ab172730) instead of ab290643 in KATO III treated with 100ng/ml IFN gamma and 100 ng/ml TNF alpha for 16 hours whole cell lysate
Blocking and dilution buffer and concentration : 5% NFDM/TBST.
Exposure time : 3.25 seconds
All lanes:
Immunoprecipitation - Anti-CXCL9 antibody [EPR26512-118] (ab290643)
Predicted band size: 14 kDa
Observed band size: 14 kDa
false
- WB
Supplier Data
Western blot - Anti-CXCL9 antibody [EPR26512-118] (AB290643)
Blocking and diluting buffers and concentration was 5% NFDM/TBST.
Exposure time : 7.75 seconds.
The expression of CXCL9 is upregulated in response to TNF gamma and LPS treatment (PMID : 12946268, 20650898).
All lanes:
Western blot - Anti-CXCL9 antibody [EPR26512-118] (ab290643) at 1/1000 dilution
Lane 1:
Untreated THP-1 (human monocytic leukemia monocyte) whole cell lysate at 20 µg
Lane 2:
THP-1 treated with 200ng/ml IFN gamma and 50 ng/ml LPS(Lipopolysaccharide) for 24 hours whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 14 kDa
Observed band size: 14 kDa
false
- WB
Supplier Data
Western blot - Anti-CXCL9 antibody [EPR26512-118] (AB290643)
Blocking and diluting buffers and concentration was 5% NFDM/TBST.
Exposure time : 5.5 seonds.
The expression of CXCL9 is upregulated in response to IFN gamma and TNF alpha treatment (PMID : 12946268, 20650898).
All lanes:
Western blot - Anti-CXCL9 antibody [EPR26512-118] (ab290643) at 1/1000 dilution
Lane 1:
Untreated KATO III (human gastric carcinoma) whole cell lysate at 20 µg
Lane 2:
KATO III treated with 100ng/ml IFN gamma and 100 ng/ml TNF alpha for 16 hours whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 14 kDa
Observed band size: 14 kDa
false
- WB
Supplier Data
Western blot - Anti-CXCL9 antibody [EPR26512-118] (AB290643)
Blocking and diluting buffers and concentration was 5% NFDM/TBST.
Exposure time : 10 seonds.
This antibody does not cross-react with CXCL10, CXCL11, or CXCL2 protein.
All lanes:
Western blot - Anti-CXCL9 antibody [EPR26512-118] (ab290643) at 1/1000 dilution
Lane 1:
HEK-293T (human embryonic kidney) cells transfected with a human CXCL9 expression vector containing a myc-His tag whole cell lysate at 4 µg
Lane 2:
HEK-293T cells transfected with a human CXCL10 expression vector containing a myc-His tag whole cell lysate at 20 µg
Lane 3:
HEK-293T cells transfected with a human CXCL11 expression vector containing a myc-His tag whole cell lysate at 40 µg
Lane 4:
HEK-293T cells transfected with a human CXCL2 expression vector containing a myc-His tag whole cell lysate at 20 µg
Secondary
All lanes:
Western blot - Goat Anti-Rabbit IgG H&L (HRP) (<a href='/en-us/products/secondary-antibodies/goat-rabbit-igg-h-l-hrp-ab97051'>ab97051</a>) at 1/100000 dilution
Predicted band size: 14 kDa
Observed band size: 14 kDa
false
Exposure time: 10s
Related conjugates and formulations (3)
-
Anti-CXCL9 antibody [EPR26512-118] - BSA and Azide free
-
665 Alexa Fluor® 647
Alexa Fluor® 647 Anti-CXCL9 antibody [EPR26512-118]
-
519 Alexa Fluor® 488
Alexa Fluor® 488 Anti-CXCL9 antibody [EPR26512-118]
Reactivity data
Product details
What is this antibody validated in?
Anti-CXCL9 antibody [EPR26512-118] (ab290643) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB), Flow Cytometry (Intra), Flow Cytometry (Flow Cyt), Immunoprecipitation (IP), Immunohistochemistry (IHC-P), Immunocytochemistry/immunofluorescence (ICC/IF) in Human samples.
What is the molecular weight of CXCL9?
Anti-CXCL9 [EPR26512-118] (ab290643) specifically detects a band for CXCL9 (UniProt: Q07325) at a molecular weight of 14kDa.
Trial sizes available!
Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10µl. Discover our selection of trial-size antibodies.
Other related products
We have a range of other formats of antibody clone [EPR26512-118] also available for your convenience: ab290643, Carrier free - ab290654, Alexa Fluor® 647 - ab308431, Alexa Fluor® 488 - ab308597
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purification technique
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
This cytokine plays a pivotal role in the immune system by regulating leukocyte trafficking. CXCL9 exerts its function through binding to the CXCR3 receptor attracting T cells towards sites of inflammation or infection. This interaction is significant in mediating immune surveillance and host defense. CXCL9 does not form part of a larger protein complex but its chemokine activity is critical for immune system coordination. Scientific studies often highlight its involvement through CXCL9 function and expression analysis.
Pathways
CXCL9 significantly influences the chemokine signaling pathway and the Th1-type adaptive immune response. Within these pathways it interacts closely with other chemokines like CXCL10 and CXCL11 which also bind to the CXCR3 receptor. These pathways highlight the coordinated mobilization of T cells during immune challenges and inflammation emphasizing how CXCL9 is often examined alongside these related chemokines in research settings.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (5)
Recent publications for all applications. Explore the full list and refine your search
BMC immunology 26:61 PubMed40836320
2025
Applications
Unspecified application
Species
Unspecified reactive species
Inflammation : PubMed40608219
2025
Applications
Unspecified application
Species
Unspecified reactive species
NPJ precision oncology 8:176 PubMed39117688
2024
Applications
Unspecified application
Species
Unspecified reactive species
The Journal of clinical investigation 134: PubMed39024569
2024
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in genetics 14:1083615 PubMed36861127
2023
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com